Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports
Status:
Not yet recruiting
Trial end date:
2022-03-08
Target enrollment:
Participant gender:
Summary
Rivaroxaban has been developed in the various clinical settings.Although cancer-associated
DVT or PE was included in previously programs, limited patients of the total populations were
cancer patients with totally implantable access ports in these studies. In this sense,
investigators feel that new oral anticoagulants should be re-investigated in this highly
specific patients group.Therefore, investigators are planning to conduct a prospective study
to estimate the efficacy and safety of rivaroxaban for thromboprophylaxis in high-risk cancer
patients with totally implantable access ports.